November 6, 2025

To whom it may concern:

Company name: SanBio Co., Ltd.
Representative: Keita Mori, Representative Director and President
(Code Number: 4592 Tokyo Stock Exchange-Growth)
Contact: Yoshihiro Kakutani, Corporate Officer, Management Administration
(TEL. +81-3-6264-3481)

Announcement of Determination of Issue Price and Other Matters for Issuance of New Shares Through an International Offering

SanBio Co., Ltd. (the “Company”) hereby announces that the Company has determined the issue price and other matters in relation to the issuance of new shares through an international offering (the “International Offering”), as resolved at the meeting of the Board of Directors dated November 6, 2025, as follows.

1. Issuance of New Shares through the International Offering

(1)	Issue Price (Offer Price) (Note)		2,487 yen per share
(2)	Total Amount of Issue Price (Offer Price) (Note)		14,922,000,000 yen
(3)	Amount to be Paid in		2,377.64 yen per share
(4)	Total Amount to be Paid in		14,265,840,000 yen
(5)	Amount of Capital Stock and Capital Surplus to be Increased	Amount of Increase in Capital Stock	7,132,920,000 yen
		Amount of Increase in Capital Surplus	7,132,920,000 yen
(6)	Payment Date		November 21, 2025 (Fri)
(7)	Delivery Date		November 25, 2025 (Tue)

Note: The underwriter will purchase and underwrite the shares at the amount to be paid in and offer the shares at the issue price (the offer price)

Reference

1. Calculation of Issue Price (Offer Price)

(1)	Calculation Reference Date and Price	November 6, 2025 (Thu)	2,734 yen
(2)	Discount Rate		9.03%

2. Intended Use of Funds Raised

The estimated net proceeds of 14,202 million yen from the International Offering are expected to be applied to:
1) 1,393 million yen by the end of December 2027 for the establishment of AKUUGO® adoption infrastructure in Japan, primarily for preparation and implementation of post-marketing clinical trials and their data analysis, as well as for the establishment of mechanisms infrastructure to ensure the safe and appropriate use of AKUUGO®.
2) 9,442 million yen by the end of December 2027 for the costs pertaining to clinical trials for the SB623 traumatic brain injury program in the U.S. market, primarily covering the development of clinical trial protocols, the conduct of clinical trials and the analysis of these data.
3) 3,367 million yen by the end of December 2027 for the costs pertaining to clinical trials for the SB623 cerebral infarction program in Japan, primarily covering the development of clinical trial protocols, the conduct of clinical trials and the analysis of these data.

[End of Document]

Note on translation
This is a translation of the original Japanese document and is provided for informational purpose only. If there are any discrepancies between this and the original, the original Japanese document prevails.